Transporter-mediated drug–drug interactions: advancement in models, analytical tools, and regulatory perspective
- 2 June 2021
- journal article
- other
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 53 (3) , 285-320
Abstract
Drug–drug interactions mediated by transporters are a serious clinical concern hence a tremendous amount of work has been done on the characterization of the transporter-mediated proteins in humans and animals. The underlying mechanism for the transporter-mediated drug–drug interaction is the induction or inhibition of the transporter which is involved in the cellular uptake and efflux of drugs. Transporter of the brain, liver, kidney, and intestine are major determinants that alter the absorption, distribution, metabolism, excretion profile of drugs, and considerably influence the pharmacokinetic profile of drugs. As a consequence, transporter proteins may affect the therapeutic activity and safety of drugs. However, mounting evidence suggests that many drugs change the activity and/or expression of the transporter protein. Accordingly, evaluation of drug interaction during the drug development process is an integral part of risk assessment and regulatory requirements. Therefore, this review will highlight the clinical significance of the transporter, their role in disease, possible cause underlying the drug–drug interactions using analytical tools, and update on the regulatory requirement. The recent in-silico approaches which emphasize the advancement in the discovery of drug–drug interactions are also highlighted in this review. Besides, we discuss several endogenous biomarkers that have shown to act as substrates for many transporters, which could be potent determinants to find the drug–drug interactions mediated by transporters. Transporter-mediated drug–drug interactions are taken into consideration in the drug approval process therefore we also provided the extrapolated decision trees from in-vitro to in-vivo, which may trigger the follow-up to clinical studies.Keywords
Funding Information
- National Mission on Himalayan Studies (GBPI/NMHS-, -18/HSF-02)
- Ministry of Environment, Forest and Climate Change, Government of India
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India
This publication has 213 references indexed in Scilit:
- The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRPAntimicrobial Agents and Chemotherapy, 2012
- The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in CancerAnnual Review of Pharmacology and Toxicology, 2012
- Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomicsBritish Journal of Pharmacology, 2011
- MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transportBiochemical Pharmacology, 2011
- Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2011
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapyBritish Journal of Clinical Pharmacology, 2008
- Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon CancerCancer Research, 2008
- Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3European Journal of Pharmacology, 2008
- Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2): A Potential Prodrug TargetMolecular Pharmaceutics, 2006